COVID-19 Incidence Among Sixth Through Twelfth Grade Students by Vaccination Status

Thakkar, Pavan V.; Zimmerman, Kanecia O.; Brookhart, M. Alan; Erickson, Tyler R; Benjamin, Daniel K.; Kalu, Ibukunoluwa C.

doi:10.1542/peds.2022-056230

Cited by 6 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 The BNT162b2 vaccine (Pfizer/BioNTech) is recommended as a 2-dose primary series with a third dose administered at least 5 months after the second dose for adolescents aged 12 to 17 years of age in the US. 3 Limited data describing vaccine effectiveness (VE) of BNT162b2 in this age group are available, [4][5][6][7][8][9][10][11] and to our knowledge, only 2 preprint reports 11,12 and 2 published reports 13,14 have estimated VE against Omicron. Both preprint reports 11,12 evaluated VE primarily against infection or symptomatic COVID-19 only.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEData about the duration of protection of 2 and 3 doses of BNT162b2 in children and adolescents are needed to help inform recommendations for boosters in this age group. OBJECTIVE To evaluate vaccine effectiveness (VE) and durability associated with 2 doses of BNT162b2 against Delta-and Omicron-related emergency department (ED) and urgent care (UC) encounters among adolescents aged 12 to 17 years and to estimate VE associated with 3 doses against these same outcomes. DESIGN, SETTING, AND PARTICIPANTS This test-negative case-control study was conducted at Kaiser Permanente Southern California, an integrated health care system using electronic health records in the US. Participants included Kaiser Permanente Southern California members ages 12 to 17 years with an ED or UC encounter from November 1, 2021, through March 18, 2022, for acute respiratory infection who were tested for SARS-CoV-2 via a reverse transction-polymerase chain reaction test. Analyses were conducted from March 21 to June 22, 2022. EXPOSURES BNT162b2 vaccination status ascertained from electronic health records and state registry data. MAIN OUTCOMES AND MEASURES The main outcome was VE associated with BNT162b2 against ED and UC encounters related to Delta or Omicron variant SARS-CoV-2 infection. RESULTSAnalyses were conducted among 3168 adolescents, including 1004 with ED visits and 2164 with UC visits. Median (IQR) age was 15 (13-16) years, and 1461 (46.1%) were boys. In adjusted analyses, VE associated with 2 doses of BNT162b2 against ED or UC encounters was highest within the first 2 months for both Delta (89% [95% CI, 69% to 96%]) and Omicron (73% [95% CI, 54% to 84%]) variants but waned to 49% (95% CI, 27% to 65%) for the Delta variant and 16% (95% CI, −7% to 34%) for the Omicron variant at 6 months and beyond. A third dose of BNT162b2 was associated with improved protection against the Omicron variant (87% [95% CI, 72% to 94%]) after a median (IQR) of 19 (9-32) days after dose 3. CONCLUSIONS AND RELEVANCEThese findings suggest that 2 doses of the BNT162b2 COVID-19 vaccine were associated with high levels of protection against ED and UC encounters related to the Delta and Omicron variants of SARS-CoV-2 in the first few months after vaccination. However, effectiveness waned over time, especially against Omicron. A third dose of BNT162b2 was associated with improved protection against Omicron beyond that seen initially after 2 doses, underscoring the importance of boosters for adolescents aged 12 to 17 years.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In our study, it was determined that 79.9% of the participants were vaccinated against Covid-19. Thakkar et al has reported that 829 (73.5%) students were vaccinated in their study conducted with 1128 students in the South Carolina region 20 . The frequency of those in the 0-19 age group who received at least one dose of vaccine was 62.95% in Hong Kong and 45.7% in Italy 21 .…”

Section: Discussionmentioning

confidence: 92%

Examination of Adolescents' E-Health Literacy Levels in Terms of Internet Usage and Some Variables Related to Covid-19

CAN,

KURTULUŞ

2023

Dicle Tıp Dergisi

View full text Add to dashboard Cite

Objective: E-Health literacy is important for obtaining accurate health information, promote and encourge health. The aim of this study is to examine of adolescents their internet usage habits, Covid-19 infection status, Covid-19 vaccination status and their views on the Covid-19 vaccine in terms of the e-health literacy levels. Methods: This cross-sectional design study was carried out among to 442 students in a high school in the 2021-2022 academic year. The independent variable of this study is the e-health literacy level of adolescents, the dependent variables are their internet usage habits, Covid-19 infection status, Covid-19 vaccination status and their some views on the Covid-19 vaccine. Results: It was determined that there was a statistically significant difference in the e-Health Literacy Scale mean scores of those who thought that internet use was important and useful in making health-related decisions (respectively 15.630 /0.000; 2,656 / 0.030). There was no statistically significant difference between having had a Covid-19 infection, being vaccinated against Covid-19, and e-Health literacy score averages (respectively 0.534/0.594; 1.032/0.302). Conclusion: According to the research results, we recommend that awareness studies be carried out to increase the e-Health literacy level of the young population and to use digital media efficiently to correct incorrect health information.

show abstract

“…Subsequent transmission studies from large exposures or household studies have shown that children are as likely to become infected as adults and are able to transmit the virus to others [5,6]. However, with appropriate precautions, COVID-19 transmission from children, such as in in-person school settings, has been rare, particularly amongst vaccinated students [7][8][9][10].…”

Section: Covid-19 Infections In Childrenmentioning

confidence: 99%

Overview of COVID-19 Infection, Treatment, and Prevention in Children

Kao

2024

JCM

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by the novel respiratory virus—severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—was declared a global pandemic by the World Health Organization on 11 March 2020. Since then, substantial gains have been made in our understanding of COVID-19 epidemiology, disease presentation, and management. While children tend to have less severe disease courses compared to adults, children can still develop severe COVID-19 infections, particularly in those with underlying medical conditions such as obesity, chronic lung disease, or prematurity. In addition, children are at risk of severe complications of COVID-19 infection, such as multisystem inflammatory syndrome in children (MIS-C) or long COVID. The case definitions of MIS-C and long COVID have continued to evolve with the increased understanding of these new entities; however, improved methods of diagnosis and determination of the optimal management are still needed. Furthermore, with the continued circulation of SARS-CoV-2 variants, there remains a need for clinicians to remain up-to-date on the latest treatment and prevention options. The purpose of this review is to provide an evidence-based review of what we have learned about COVID-19 in children since the start of the pandemic and how best to counsel children and their families on the best methods of prevention.

show abstract

COVID-19 Incidence Among Sixth Through Twelfth Grade Students by Vaccination Status

Cited by 6 publications

References 6 publications

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years

Examination of Adolescents' E-Health Literacy Levels in Terms of Internet Usage and Some Variables Related to Covid-19

Overview of COVID-19 Infection, Treatment, and Prevention in Children

Contact Info

Product

Resources

About